vTv Therapeutics Inc.

News & Events

Press Releases

In The Media

1. vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

   GlobeNewswire MAR 20, 2025 5:35 PM EDT
   Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 tria...
   READ ARTICLE

2. vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

   GlobeNewswire MAR 17, 2025 8:30 AM EDT
   Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes ...
   READ ARTICLE

3. CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

   PR Newswire DEC 9, 2024 7:33 AM EST
   CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF B...
   READ ARTICLE

4. vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

   GlobeNewswire DEC 2, 2024 4:05 PM EST
   HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clini...
   READ ARTICLE

5. vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update

   GlobeNewswire NOV 12, 2024 4:05 PM EST
   HIGH POINT, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clini...
   READ ARTICLE

6. vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

   GlobeNewswire AUG 8, 2024 4:15 PM EDT
   Screened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D); working to resol...
   READ ARTICLE

7. vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

   GlobeNewswire JUL 26, 2024 4:05 PM EDT
   HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late ...
   READ ARTICLE

8. vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

   GlobeNewswire JUN 24, 2024 4:05 PM EDT
   Cadisegliatin is a potential first-in-class oral liver selective ...
   READ ARTICLE

9. vTv Therapeutics Announces Deepa Prasad as New President and CEO

   Canada Newswire OCT 20, 2021 9:00 AM EDT
   vTv Therapeutics Announces Deepa Prasad as New President and CEO PR Newswire ...
   READ ARTICLE

10. Volatility Creates Opportunity, Insights on Price Data - Research on vTv Therapeutics, Golden Entertainment, NCI Inc., and Avinger Inc.

    ACCESS Newswire DEC 7, 2015 8:35 AM EST
    NEW YORK, NY / ACCESSWIRE / December 7, 2015 / Moments ago, Trader's Choice released new res...
    READ ARTICLE